J2S-MC-GZMT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-C
BrenipatidePlacebo to match LYBrenipatideBrenipatide
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.